Belumosudil
Rezurock (belumosudil) is a small molecule pharmaceutical. Belumosudil was first approved as Rezurock on 2021-07-16. It is used to treat graft vs host disease in the USA. The pharmaceutical is active against rho-associated protein kinase 1 and rho-associated protein kinase 2.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
|---|---|
| immune system diseases | D007154 |
Trade Name
FDA
EMA
Rezurock
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| rezurock | New Drug Application | 2025-04-29 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| graft vs host disease | — | D006086 | D89.81 |
Agency Specific
FDA
EMA
Expiration | Code | ||
|---|---|---|---|
BELUMOSUDIL MESYLATE, REZUROCK, KADMON PHARMS LLC | |||
| 2028-07-16 | ODE-362 | ||
| 2026-07-16 | NCE | ||
HCPCS
No data
Clinical
Clinical Trials
37 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Graft vs host disease | D006086 | — | D89.81 | — | 7 | 1 | 1 | — | 9 |
| Bronchiolitis obliterans syndrome | D000092122 | — | D89.811 | — | 7 | 1 | 1 | — | 9 |
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Graft rejection | D006084 | — | — | — | — | 1 | — | — | 1 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Psoriasis | D011565 | EFO_0000676 | L40 | — | 3 | — | — | — | 3 |
| Systemic scleroderma | D012595 | EFO_0000717 | M34 | — | 2 | — | — | — | 2 |
| Diffuse scleroderma | D045743 | EFO_0000404 | — | — | 2 | — | — | — | 2 |
| Sclerosis | D012598 | — | — | — | 2 | — | — | — | 2 |
| Fibrosis | D005355 | — | — | 1 | 1 | — | — | — | 2 |
| Multiple myeloma | D009101 | — | C90.0 | 1 | 1 | — | — | — | 1 |
| Plasma cell neoplasms | D054219 | — | — | 1 | 1 | — | — | — | 1 |
| Idiopathic pulmonary fibrosis | D054990 | — | J84.112 | — | 1 | — | — | — | 1 |
| Pulmonary fibrosis | D011658 | — | J84.10 | — | 1 | — | — | — | 1 |
| Lung diseases | D008171 | EFO_0003818 | J98.4 | — | 1 | — | — | — | 1 |
Show 3 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Immune system diseases | D007154 | — | D89.9 | 4 | — | — | — | — | 4 |
| Autoimmune diseases | D001327 | EFO_0000540 | M30-M36 | 2 | — | — | — | — | 2 |
| Drug interactions | D004347 | — | — | 1 | — | — | — | — | 1 |
| Healthy volunteers/patients | — | — | — | 1 | — | — | — | — | 1 |
| Liver diseases | D008107 | EFO_0001421 | K70-K77 | 1 | — | — | — | — | 1 |
| Hepatic insufficiency | D048550 | — | — | 1 | — | — | — | — | 1 |
| Biological availability | D001682 | — | — | 1 | — | — | — | — | 1 |
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Belumosudil |
| INN | belumosudil |
| Description | Belumosudil, sold under the brand name Rezurock among others, is a medication used for the treatment of chronic graft versus host disease (cGvHD). It is in the class of drugs known as serine/threonine kinase inhibitors. Specifically, it is an inhibitor of Rho-associated coiled-coil kinase 2 (ROCK2; ROCK-II). Belumosudil binds to and inhibits the serine/threonine kinase activity of ROCK2. This inhibits ROCK2-mediated signaling pathways which play major roles in pro- and anti-inflammatory immune cell responses. A genomic study in human primary cells demonstrated that the drug also has effects on oxidative phosphorylation, WNT signaling, angiogenesis, and KRAS signaling.
|
| Classification | Small molecule |
| Drug class | vasodilators (undefined group): Rho protein kinase (ROCK) inhibitors |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | CC(C)NC(=O)COc1cccc(-c2nc(Nc3ccc4[nH]ncc4c3)c3ccccc3n2)c1 |
Identifiers
| PDB | — |
| CAS-ID | 911417-87-3 |
| RxCUI | — |
| ChEMBL ID | CHEMBL2005186 |
| ChEBI ID | — |
| PubChem CID | 11950170 |
| DrugBank | DB16703 |
| UNII ID | 834YJF89WO (ChemIDplus, GSRS) |
Target
Agency Approved
ROCK1
ROCK1
ROCK2
ROCK2
Organism
Homo sapiens
Gene name
ROCK1
Gene synonyms
NCBI Gene ID
Protein name
rho-associated protein kinase 1
Protein synonyms
p160 ROCK-1, p160ROCK, Renal carcinoma antigen NY-REN-35, Rho-associated, coiled-coil-containing protein kinase 1, Rho-associated, coiled-coil-containing protein kinase I, ROCK-I
Uniprot ID
Mouse ortholog
Rock1 (19877)
rho-associated protein kinase 1 (Q8C7H0)
Alternate
No data
Variants
No data
Financial
Estimated US medical usage
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 489 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
2,507 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use